Denis L
Department of Urology, A. Z. Middelheim, Antwerp, Belgium.
Cancer. 1993 Feb 1;71(3 Suppl):1050-8. doi: 10.1002/1097-0142(19930201)71:3+<1050::aid-cncr2820711425>3.0.co;2-#.
No other treatment matches the 40-60% objective response and up to 80% subjective responses for primary hormonal therapy in patients with symptomatic disease. This makes primary hormonal treatment first-line therapy metastatic prostate cancer.
The treatment outcome is determined by the initial and intermittent prognostic factors. In the multihormonal environment, several endocrine treatments have shown competing levels of response. Maximal androgen blockade has emerged as the best treatment to achieve a response and even has increased survival modestly. Monotherapy with nonsteroidal antiandrogens plays a role in patients trying to preserve their potency.
Pilot treatment adjusted to the medical needs and social preferences of the patient is appropriate and allows a tailored approach to the individual patient.
